A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Karim Fizazi, M.D., Ph.D.
Institut Gustave Roussy, University of Paris
Principal InvestigatorKOL profile → - Sebastien J Hotte, M.D.
Juravinski Cancer Centre, McMaster University
Principal Investigator - Tomasz M Beer, M.D.
Oregon Health and Science University
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
33 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Facility name not stated
Winnipeg, Manitoba, Canada
- Facility name not stated
Hamilton, Ontario, Canada
- Facility name not stated
Lyon, France
- Facility name not stated
Paris, France
- Facility name not stated
Saint-Herblain, France
- Facility name not stated
Villejuif, France
- Facility name not stated
Barcelona, Spain
- Facility name not stated
Madrid, Spain
- Facility name not stated
Pamplona, Spain
- Facility name not stated
Sabadell, Spain
- Facility name not stated
Valencia, Spain
- Facility name not stated
Cambridge, United Kingdom
- Facility name not stated
Sutton, United Kingdom
- Facility name not stated
La Verne, California, United States
- Facility name not stated
Fort Lauderdale, Florida, United States
- Facility name not stated
Tampa, Florida, United States
- Facility name not stated
Honolulu, Hawaii, United States
- Facility name not stated
Urbana, Illinois, United States
- Facility name not stated
Metairie, Louisiana, United States
- Facility name not stated
Baltimore, Maryland, United States
- Facility name not stated
Burlington, Massachusetts, United States
- Facility name not stated
Detroit, Michigan, United States
- Facility name not stated
Kansas City, Missouri, United States
- Facility name not stated
Omaha, Nebraska, United States
- Facility name not stated
Las Vegas, Nevada, United States
- Facility name not stated
Syracuse, New York, United States
- Facility name not stated
Raleigh, North Carolina, United States
- Facility name not stated
Canton, Ohio, United States
- Facility name not stated
Oklahoma City, Oklahoma, United States
- Facility name not stated
Portland, Oregon, United States
- Facility name not stated
Columbia, South Carolina, United States
- Facility name not stated
Memphis, Tennessee, United States
- Facility name not stated
Tyler, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Mar 2010
- Primary completion
- 31 Mar 2013
- Completion
- 31 Mar 2013
- Last update posted
- 12 Oct 2016
- Registered enrollment
- 14
- Registry id
- NCT01083615
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.